StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company
February 28, 2019 6:51 AM
RBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $192.00 (from $199.00) while maintaining ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst EPS View
Analyst PT Change
Next Articles
Sarepta Therapeutics (SRPT) PT Raised To $230 At Nomura On Increasing Pipeline Success
February 28, 2019 6:23 AM
Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen
February 28, 2019 6:21 AM
Form 8-K Sarepta Therapeutics, For: Feb 27
February 27, 2019 4:26 PM
Sarepta Therapeutics (SRPT) Tops Q4 EPS by 19c, Revenues Miss
February 27, 2019 4:15 PM
Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments
February 27, 2019 4:05 PM
Sarepta (SRPT) Phase I/IIa MYO-101 Trial Data 'Striking' - SunTrust
February 27, 2019 11:55 AM
Sarepta Therapeutics (SRPT) Announces Positive Expression, Biomarker Data from Three-Patient Cohort Dosed in MYO-101 Gene Therapy Trial to Treat LGMD2E, or Beta-Sarcoglycanopathy
February 27, 2019 9:03 AM
Sarepta Therapeutics Announces Positive and Robust Expression and Biomarker Data from the First Three-Patient Cohort Dosed in the MYO-101 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Typ
February 27, 2019 9:01 AM
Sarepta Therapeutics (SRPT) Hits Pre-market High, Up 7% with Conference Call Onoing
February 27, 2019 8:16 AM
Sarepta Therapeutics (SRPT) Exercises Option to Acquire Myonexus Therapeutics
February 27, 2019 7:35 AM
